Skip to main content

ACTOplus met FDA Approval History

FDA Approved: Yes (First approved August 29, 2005)
Brand name: ACTOplus met
Generic name: pioglitazone and metformin
Dosage form: Tablets
Company: Takeda Pharmaceuticals
Treatment for: Type 2 Diabetes

ACTOplus met (pioglitazone and metformin) is a combination antihyperglycemic medication used in the management of type 2 diabetes.

Development timeline for ACTOplus met

DateArticle
May 13, 2009Approval FDA Approves ACTOplus met XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes
Aug 29, 2005Approval ACTOplus met Takeda Pharmaceuticals - Treatment for Type 2 Diabetes
Oct 29, 2004Takeda Submits New Drug Application for Combination Type 2 Diabetes Medication, Actoplus Met (pioglitazone HCl and metformin HCl)

See also

ACTOplus met (pioglitazone and metformin) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer